Similar articles

• [Alfuzosin in the treatment of benign prostatic hypertrophy].

  Jardin A. Jardin A. J Urol (Paris). 1993;99(6):308-10. J Urol (Paris). 1993. PMID: 7516375 Clinical Trial. French. No abstract available.
• Alfuzosin for benign prostatic hypertrophy.

  Chapple CR. Chapple CR. Lancet. 1991 Jul 20;338(8760):182. doi: 10.1016/0140-6736(91)90167-n. Lancet. 1991. PMID: 1712882 No abstract available.
• [Alfuzosin. A new selective alpha 1 receptor antagonist for symptomatic medical treatment of benign prostatic hypertrophy prior to surgery].

  Hansen BJ, Meyhoff HH. Hansen BJ, et al. Ugeskr Laeger. 1992 Feb 3;154(6):361-2. Ugeskr Laeger. 1992. PMID: 1371629 Danish. No abstract available.
• Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

  Wilde MI, Fitton A, McTavish D. Wilde MI, et al. Drugs. 1993 Mar;45(3):410-29. doi: 10.2165/00003495-199345030-00008. Drugs. 1993. PMID: 7682910 Review.
• Alfuzosin for the management of benign prostate hyperplasia.

  Weiner DM, Lowe FC. Weiner DM, et al. Expert Opin Pharmacother. 2003 Nov;4(11):2057-63. doi: 10.1517/14656566.4.11.2057. Expert Opin Pharmacother. 2003. PMID: 14596659 Review.